Bluelinea Société Anonyme Valuation

Is ALBLU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALBLU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALBLU's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALBLU's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALBLU?

Key metric: As ALBLU is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALBLU. This is calculated by dividing ALBLU's market cap by their current revenue.
What is ALBLU's PS Ratio?
PS Ratio	1.1x
Sales	€9.64m
Market Cap	€11.05m

ALBLU key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.6x
Enterprise Value/EBITDA	592.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ALBLU's PS Ratio compare to its peers?

The above table shows the PS ratio for ALBLU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.5x
ALMKT Mauna Kea Technologies	1.4x	8.0%	€11.3m
ALDMS Diagnostic Medical Systems	0.3x	n/a	€13.5m
ALSGD SpineGuard	2.4x	n/a	€11.0m
ALIMP Implanet	2.1x	n/a	€15.1m
ALBLU Bluelinea Société Anonyme	1.1x	n/a	€11.1m

Price-To-Sales vs Peers: ALBLU is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (1.5x).

Price to Sales Ratio vs Industry

How does ALBLU's PS Ratio compare vs other companies in the FR Medical Equipment Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
GBT Guerbet	0.4x	6.1%	US$344.01m
ALBIO Biosynex	0.3x	n/a	US$31.04m
ALDMS Diagnostic Medical Systems	0.3x	n/a	US$14.06m
ALEMG Laboratoires Euromedis Société anonyme	0.4x	8.3%	US$13.74m

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ALBLU is good value based on its Price-To-Sales Ratio (1.1x) compared to the European Medical Equipment industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is ALBLU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALBLU PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ALBLU's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratoires Euromedis Société anonyme

€13.2m

Through its subsidiaries, designs, manufactures, and distributes medical equipment under the Euromedis brand name for healthcare professionals, local communities, and individuals in France and internationally.

ALEMG

€4.63

-2.9%

emeis Société anonyme

€839.2m

Operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals.

EMEIS

€5.21

-11.0%

-97.8%

bioMérieux

€11.6b

Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

BIM

€98.70

0.4%

0.08%